Keynote Session
Bardia A et al. Randomized phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: Efficacy, safety and biomarker results from TROPION-Breast01. San Antonio Breast Cancer Symposium 2023;Abstract GS02-01.
Goetz M et al. MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2- advanced breast cancer. San Antonio Breast Cancer Symposium 2023;Abstract GS01-12.
Hamilton EP et al. A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC). ASCO 2023;Abstract 1004.
Huppert L et al. Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC). San Antonio Breast Cancer Symposium 2023;Abstract PS08-04.
Jhaveri K et al. Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study. ESMO 2023;Abstract 383MO.
Jhaveri K et al. Phase III study of inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: INAVO120 primary analysis. San Antonio Breast Cancer Symposium 2023;Abstract GS03-13.
Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. ESMO 2023;Abstract 376O.
Munster P et al. Report on cohort expansion of phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2 low breast cancer. San Antonio Breast Cancer Symposium 2023;Abstract RF02-05.
Rugo HS et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial. Lancet 2023;402(10411):1423-33. Abstract
Slamon DJ et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol 2024;42(9):994-1000. Abstract
Tolaney SM et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). ASCO 2023;Abstract 1003.
Turner NC et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 2023;388(22):2058-70. Abstract
Wu J et al. BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic breast cancer and other solid tumors: Results from a phase 1 study. San Antonio Breast Cancer Symposium 2023;Abstract PS08-07.
Wu J et al. First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors. ESMO 2023;Abstract 381O.
Module 1: Hodgkin and Non-Hodgkin Lymphoma
Abramson JS et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: Primary analysis of the phase 3 TRANSFORM study. Blood 2023;141(14):1675-84. Abstract
Abramson JS et al. TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma. ASH 2023;Abstract 602.
Ayyappan S et al. Final analysis of the phase 2 ELM-2 study: Odronextamab in patients with relapsed/refractory (R/R) diffuse large b-cell lymphoma (DLBCL). ASH 2023;Abstract 436.
Caimi PF et al. Long-term responses with loncastuximab tesirine: updated results from LOTIS-2, the pivotal phase 2 study in patients with relapsed/refractory diffuse large B-cell lymphoma. EHA 2023;Abstract P1132.
Cohen JB et al. Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study. ASH 2023;Abstract 981.
Crombie JL et al. Odronextamab demonstrates durable complete responses in patients with diffuse large b-cell lymphoma (DLBCL) progressing after CAR-T therapy: Outcomes from the ELM-1 study. ASH 2023;Abstract 4461.
Falchi L et al. EPCORE FL-1: Phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R2) vs R2 alone in patients with relapsed or refractory follicular lymphoma. ASH 2023;Abstract 3053.
Federico M et al. Long-term follow-up of the response-adapted intergroup EORTC/LYSA/FIL H10 trial for localized Hodgkin lymphoma. J Clin Oncol 2024;42(1):19-25. Abstract
Herrera AF et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). ASCO 2023;Abstract LBA4.
Hutchings M et al. Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume. ASH 2023;Abstract 433.
Jurczak W et al. Longer follow-up from the pivotal Epcore NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable complete remissions in patients with relapsed/refractory large B-cell lymphoma. EHA 2023;Abstract P1118.
Karimi Y et al. Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial. ASCO 2023;Abstract 7525.
Kumar A et al. A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma. ASH 2023;Abstract 738.
Linton K et al. Epcoritamab SC monotherapy leads to deep and durable responses in patients with relapsed or refractory follicular lymphoma: First data disclosure from the Epcore NHL-1 follicular lymphoma dose-expansion cohort. ASH 2023;Abstract 1655.
Morschhauser F et al. TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma. ASH 2023;Abstract 602.
Neelapu SS et al. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 2024;143(6):496-506. Abstract
Thieblemont C et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I/II trial. J Clin Oncol 2023;41(12):2238-47. Abstract
Wang M et al. Ibrutinib combined with venetoclax in patients with relapsed/refractory mantle cell lymphoma: Primary analysis results from the randomized phase 3 Sympatico study. ASH 2023;Abstract LBA-2.
Wang X et al. Retraction statement: Ding, J., Wang, X., Gao, J. and Song, T. (2021), Silencing of cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma. FEBS Open Bio, 11: 2186-2197. FEBS Open Bio 2023;13(8):1540. Abstract
Westin JR et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 2023;389(2):148-57. Abstract
Zinzani PL et al. ROSEWOOD: A phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma. J Clin Oncol 2023;41(33):5107-17. Abstract
Module 2: Gynecologic Cancers
Berg HG et al. Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value. Br J Cancer 2023;128(4):647-55. Abstract
Eskander RN et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med 2023;388(23):2159-70. Abstract
Jamieson A, McAlpine JN. Molecular profiling of endometrial cancer from TCGA to clinical practice. J Natl Compr Canc Netw 2023;21(2):210-6. Abstract
Lorusso D et al. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ ENGOT-ov25 trial. Int J Gynecol Cancer 2024;34(4):550-8. Abstract
Lorusso D et al. Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. ESMO 2023;Abstract LBA38.
Matulonis UA et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. J Clin Oncol 2023:41(13):2436-45. Abstract
Meric-Bernstam F et al. Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study. ESMO 2023;Abstract LBA34.
Mirza MR et al. Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. ESMO 2023;Abstract 740MO.
Moore KN et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023;389(23):2162-74. Abstract
Moore KN et al. Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. ASCO 2023;Abstract LBA5507.
Vergote I et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. J Clin Oncol 2023;41(35):5400-10. Abstract
Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J Clin Oncol 2024;42(3):283-99. Abstract
Module 3: Localized Breast Cancer; SABCS 2023 Review
Azim H et al. Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy. San Antonio Breast Cancer Symposium 2023;Abstract GS02-11.
Brown LC et al. Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial. ASCO 2023;Abstract 504.
Harbeck N et al. Association between baseline radiological tumor burden and outcomes in patients with metastatic breast cancer treated with an immune checkpoint inhibitor. ESMO 2023;Abstract LBA17.
Hortobagyi GN et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial. San Antonio Breast Cancer Symposium 2023;Abstract GS03-03.
Johnston S et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24(1):77-90. Abstract
Ligibel JA et al. Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial. ASCO 2023;Abstract 12001.
Loibl S et al. Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis. San Antonio Breast Cancer Symposium 2023;Abstract GS03-12.
Luen SJ et al. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Ann Oncol 2023;34(4):397-409. Abstract
Partridge AH et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med 2023;388(18):1645-56. Abstract
Schmid P et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study. San Antonio Breast Cancer Symposium 2023;Abstract LB01-01.
Slamon DJ et al. Rationale and trial design of NATALEE: A phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer. Ther Adv Med Oncol 2023;15:17588359231178125. Abstract
Slamon DJ et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. ASCO 2023;Abstract LBA500.
Module 4: Metastatic HER2-Positive and Triple-Negative Breast Cancer; SABCS 2023 Review
Abelman RO et al. Sequencing antibody-drug conjugate after antibody-drug conjugate in metastatic breast cancer (A3 study): Multi-institution experience and biomarker analysis. San Antonio Breast Cancer Symposium 2023;Abstract PS08-03.
André F et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet 2023;401(10390):1773-85. Abstract
Bardia A et al. Datopotamab deruxtecan (dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. ESMO 2023;Abstract LBA11.
Hurvitz SA et al. A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. ESMO 2023;Abstract 3770.
Hurvitz SA et al. HER2CLIMB-02: Randomized, double-blind phase 3 trial of tucatinib and trastuzumab emtansine for previously treated HER2-positive metastatic breast cancer. San Antonio Breast Cancer Symposium 2023;Abstract GS01-10.
Hurvitz SA et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet 2023;401(10371):105-17. Abstract
Marmé F et al. Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA)). Ann Oncol 2023;8(1suppl_4):101223. Abstract
Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study. ESMO 2023;Abstract 3760.
Mosele F et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: The phase 2 DAISY trial. Nat Med 2023;29(8):2110-20. Abstract
Pérez-García JM et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol 2023;25(1):157-66. Abstract
Robson M et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer 2023;184:39-47. Abstract
Rugo H et al. Pembrolizumab + olaparib vs pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy for locally recurrent inoperable or metastatic TNBC: Randomized open-label phase 2 KEYLYNK-009 study. San Antonio Breast Cancer Symposium 2023;Abstract GS01-05.
Rugo H et al. Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase 3 DESTINY-Breast04 trial. ESMO Breast 2023;Abstract 1850.
Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. ESMO 2023;Abstract 379MO.
Tolaney SM et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). ASCO 2023;Abstract 1003.
Yin Y et al. Updated efficacy and safety of SKB264 (MK-2870) for previously treated metastatic triple negative breast cancer (mTNBC) in phase 2 study. San Antonio Breast Cancer Symposium 2023;Abstract PS08-08.
Module 5: Renal Cell Carcinoma
Albiges L et al. Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study. ESMO 2023;Abstract LBA88.
Albiges L et al. Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study. Ann Oncol 2023;34:S1329-30. Abstract
Atkins MB et al. Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A). Genitourinary Cancers Symposium 2022;Abstract 362.
Choueiri TK et al. Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC). Genitourinary Cancers Symposium 2024;Abstract LBA359.
Choueiri TK et al. Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study. ASCO 2023;Abstract LBA4500.
George S et al. Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T. Genitourinary Cancers Symposium 2024;Abstract LBA360.
Lee C-H et al. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial. ASCO 2023;Abstract 4537.
Rini BI et al. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. JITC 2023. Abstract
Voss MH et al. First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study. Genitourinary Cancers Symposium 2024;Abstract 2.
Module 6: Urothelial Bladder Cancer
Apolo A et al. AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. Genitourinary Cancers Symposium 2024;Abstract LBA531.
Galsky MD et al. Extended follow-up results from the CheckMate 274 trial. Genitourinary Cancers Symposium 2023;Abstract LBA443.
Loriot Y et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med 2023;389(21):1961-71. Abstract
Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract
Necchi A et al. Pembrolizumab (pembro) monotherapy for patients (pts) with high-risk non–muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette–Guérin (BCG): Results from cohort B of the phase 2 KEYNOTE-057 trial. Genitourinary Cancers Symposium 2023;Abstract LBA442.
Necchi A et al. Results from SunRISe-1 in patients (pts) with bacillus Calmette–Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) receiving TAR-200 monotherapy. ESMO 2023;Abstract LBA105.
Necchi A et al. Results from SunRISe-1 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 monotherapy. EAU 2023. Abstract
Powles T et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024;390(10):875-88. Abstract
Powles TB et al. EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). ESMO 2023;Abstract LBA6.
Sheng X et al. Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study. ASCO 2023;Abstract 4566.
Siefker-Radtke A et al. KEYNOTE-866: Phase 3 study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC). ESMO 2023;Abstract 2075.
Van Der Heijden MS et al. Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study. Genitourinary Cancers Symposium 2023;Abstract LBA530.
Module 7: Prostate Cancer
Agarwal N et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial. Lancet 2023;402(10398):291-303. Abstract
Aggarwal R et al. PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19). J Clin Oncol 2024;42(10):1114-23. Abstract
Chi KN et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol 2023;41(18):3339-51. Abstract
Freedland S et al. Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK. ESMO 2023;Abstract 1778P.
Huggins C, Hodges CV. The effect of castration on estrogen and of androgen injection on serum phosphates in metastatic carcinoma of the prostate. CA Cancer J Clin1972;22(4):232-40. Abstract
Hussain M et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol 2023;41(20):3595-607. Abstract
Sartor O et al. Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). ESMO 2023;Abstract LBA13.
Shore N et al. EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. AUA 2023;Abstract LBA02-09.
Module 8: Targeted Therapy for Non-Small Cell Lung Cancer
Cho BC et al. Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial. ESMO 2023;Abstract LBA14.
Drilon A et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: Updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol 2023;41(2):385-94. Abstract
Girard N et al. Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study. ESMO 2023;Abstract LBA5.
Goto K et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol 2023;41(31):4852-63. Abstract
Herbst RS et al. Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). ASCO 2023;Abstract LBA3.
Janne PA et al. Osimertinib with/without platinum-based chemotherapy as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA2). WCLC 2023;Abstract PL03.13.
Mazieres J et al. Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: Long-term follow-up of the VISION phase 2 nonrandomized clinical trial. JAMA Oncol 2023;9(9):1260-6. Abstract
Nassar AH et al. Consolidation osimertinib versus durvalumab versus observation after concurrent chemoradiation in unresectable EGFR-mutant NSCLC: A multicenter retrospective cohort study. J Thorac Oncol 2024;[Online ahead of print]. Abstract
Passaro A et al. Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial. ESMO 2023;Abstract LBA15.
Solomon B et al. ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). ESMO 2023;Abstract LBA2.
Yu HA et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol 2023;41(35):5363-75. Abstract
Zhou C et al. Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions. N Engl J Med 2023;389(22):2039-51. Abstract
Module 9: Nontargeted Treatments for Lung Cancer
Ahn M et al. Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study. ESMO 2023;Abstract LBA12.
Carbone DP et al. First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS). ASCO 2023;Abstract LBA9023.
Cascone T et al. CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. ESMO 2023;Abstract LBA1.
Felip E et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase III trial. Ann Oncol 2023;34(10):907-19. Abstract
Forde PM et al. Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816. ELCC 2023;Abstract 840.
Garassino MC et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol 2023;41(11):1992-8. Abstract
Haymach JV et al. AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. AACR 2023;Abstract CT005.
Heymach JV et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 2023;389(18):1672-84. Abstract
Makharadze T et al. Cemiplimab plus chemotherapy versus chemotherapy alone in advanced NSCLC: 2-year follow-up from the phase 3 EMPOWER-Lung 3 Part 2 trial. J Thorac Oncol 2023;18(6):755-68. Abstract
Peters S et al. Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line metastatic (m) NSCLC: 5-year overall survival (OS) update from the POSEIDON study. ESMO Immuno-Oncology Congress 2023;Abstract LBA3.
Reck M et al. MDT-BRIDGE: A phase 2 study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC. ESMO 2023;Abstract 115TiP.
Wakelee HA et al. KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC. ASCO 2023;Abstract LBA100.
Wakelee H et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med 2023;389(6):491-503. Abstract
Module 10: Multiple Myeloma
Bahlis NJ et al. Venetoclax in combination with daratumumab and dexamethasone elicits deep, durable responses in patients with t(11;14) relapsed/refractory multiple myeloma: Updated analyses of minimal residual disease negativity in phase 1/2 study. ASH 2023;Abstract 338.
Bal S et al. BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): Results from a phase 1 study. EHA 2023;Abstract S193.
Bar N et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen (BCMA) × CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated results from a phase 1 first‑in‑human clinical study. ASH 2023;Abstract 2011.
Chhabra S et al. Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: Findings from the MASTER and GRIFFIN trials. Transplant Cell Ther 2023;29(3):174.e1-10. Abstract
Cohen YC et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8002.
Costa LJ et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): Final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol 2023;10(11):e890-901. Abstract
Derman BA et al. Final analysis of a phase 2 trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma (NDMM) without autologous stem cell transplantation (ASCT). ASH 2023;Abstract 4747.
Dhakal B et al. First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. ASCO 2023;Abstract LBA106.
Dimopoulos MA et al. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Am J Hematol 2023;98(1):E15-9. Abstract
Facon T et al. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple myeloma: IKEMA subgroup analysis. Haematologica 2024;109(2):604-16. Abstract
Facon T et al. Long-term outcomes with isatuximab-carfilzomib-dexamethasone (Isa-Kd) in relapsed multiple myeloma patients with 1q21+ status: Updated results from the phase 3 IKEMA study. ASCO 2023;Abstract 8029.
Ferreri C et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J 2023;13(1):117. Abstract
Gay F et al. Results of the phase III randomized Iskia trial: Isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients. ASH 2023;Abstract 4.
Glisovic-Aplenc T et al. CD38 as a pan-hematologic target for chimeric antigen receptor T cells. Blood Adv 2023;7(16):4418-30. Abstract
González-Calle V et al. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: Results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study. Haematologica 2024;[Online ahead of print]. Abstract
Jagannath S et al. Patterns of response to 200 mg linvoseltamab in patients with relapsed/refractory multiple myeloma: Longer follow-up of the Linker-MM1 study. ASH 2023;Abstract 4746.
Kawano Y et al. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: Updated IKEMA subgroup analysis. Clin Lymphoma Myeloma Leuk 2023;23(10):e360-7. Abstract
Leypoldt LB et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma. J Clin Oncol 2024;42(1):26-37. Abstract
Lin Y et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. ASCO 2023;Abstract 8009.
Martin T et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: Updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J 2023;13(1):72. Abstract
Martino EA et al. Isatuximab in multiple myeloma. Expert Opin Biol Ther 2023;23(4):315-8. Abstract
Mateos M-V et al. Results from the randomized phase III DREAMM-7 study of belantamab mafodotin (belamaf) + bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM). ASCO Plenary Series: February 2024 Session;Abstract 439572.
Mateos M-V et al. GEM2017FIT trial: induction therapy with bortezomib-melphalan and prednisone (vmp) followed by lenalidomide and dexamethasone (rd) versus carfilzomib, lenalidomide and dexamethasone (krd) plus/minus daratumumab (d), 18 cycles, followed by consolidation and maintenance therapy with lenalidomide and daratumumab: Phase III, multicenter, randomized trial for elderly fit newly diagnosed multiple myeloma (NDMM) patients aged between 65 and 80 years. ASH 2023;Abstract 209.
Mateos MV et al. Results from the randomized, open-label phase 3 CANOVA study of venetoclax versus pomalidomide added to dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma. IMS 2023;Abstract OA-52.
O’Donnell EK et al. A phase II study of isatuximab, once weekly carfilzomib, lenalidomide, dexamethasone, in newly diagnosed, transplant-eligible multiple myeloma (the SKylaRk trial). ASH 2023;Abstract 4671.
Richardson PG et al. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: Final overall survival analysis. Haematologica 2024;[Online ahead of print]. Abstract
Richardson PG et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Results from the CC-92480-MM-002 trial. ASH 2023;Abstract 1013.
Richardson PG et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med 2023;389(11):1009-22. Abstract
Richter J et al. Updated results from a matching-adjusted indirect comparison of efficacy outcomes of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma. ASH 2023;Abstract 6734.
Rodríguez-Otero P et al. Idecabtagene vicleucel (ide-cel) versus standard (std) regimens in patients (pts) with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): Updated analysis from KarMMa-3. ASH 2023;Abstract 1028.
Schinke CD et al. Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8036.
Sonneveld P et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2024;390(4):301-13. Abstract
Touzeau C et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation with tandem transplant in high-risk newly diagnosed myeloma patients: Final results of the phase 2 study IFM 2018-04. ASH 2023;Abstract 207.
van de Donk NWCJ et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8011.
Vij R et al. Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma. ASH 2023;Abstract 3378.
Voorhees PM et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): Final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 2023;10(10):e825-37. Abstract
Zhang M et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): A first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol 2023;10(2):E107-16. Abstract
Module 11: Gastroesophageal Cancers
Janjigian Y et al. Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. Gastrointestinal Cancers Symposium 2023;Abstract 4025.
Rha SY et al. KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations. ASCO 2023;Abstract 4014.
Shitara K et al. Negative hyperselection of patients with RAS wild-type metastatic colorectal cancer for panitumumab: A biomarker study of the phase III PARADIGM trial. Gastrointestinal Cancers Symposium 2023;Abstract 11.
Xu RH et al. Fruquintinib plus paclitaxel versus paclitaxel as second-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma (FRUTIGA): A randomized, multicenter, double-blind, placebo-controlled, phase 3 study. ASCO Plenary Series Virtual 2023;Abstract 438780.
Module 12: Hepatobiliary Cancers
Cannon TL et al. Pertuzumab plus trastuzumab (P+T) in patients (pts) with biliary tract cancer (BTC) with ERBB2/3 amplification (amp), overexpression (oe), or mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 2023;41(4):546. Abstract
Goyal L et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 2023;388(3):228-39. Abstract
Kelley RK et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023;401(10391):1853-65. Abstract
Lee C et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: A multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14). Lancet Gastroenterol Hepatol 2023;8(1):56-65. Abstract
Lencioni R et al. EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. Gastrointestinal Cancers Symposium 2024;Abstract LBA432.
Nakamura Y et al. Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2-positive metastatic biliary tract cancer (SGNTUC-019): A phase II basket study. J Clin Oncol 2023;41(36):5569-78. Abstract
Pant S et al. Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC). ASCO 2023;Abstract 4008.
Qin S et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial. Lancet 2023;402:1835-47. Abstract
Shubbiah V et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial. Nat Med 2023;29(5):1103-12. Abstract
Sweeney CJ et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): An international, open-label, randomised, phase 3 trial. J Clin Oncol 2023;24(4):323-34. Abstract
Module 13: Colorectal Cancers
Andre T et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. Gastrointestinal Cancers Symposium 2024;Abstract LBA768.
Dasari A et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): An international, multicentre, randomised, double-blind, phase 3 study. Lancet 2023;402(10395):41-53. Abstract
Modest DP et al. Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300. Gastrointestinal Cancers Symposium 2024;Abstract 10.
Morris VK et al. SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer. Gastrointestinal Cancers Symposium 2024;Abstract TPS234.
Prager G et al. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 2023;388(18):1657-67. Abstract
Raghav K et al. Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study. ASCO 2023;Abstract 3501.
Strickler JH et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): A multicentre, open-label, phase 2 study. Lancet Oncol 2023;24(5):496-508. Abstract
Yoshino T et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun 2023;14(1):3332. Abstract
Yukami H et al. Circulating tumor DNA (ctDNA) dynamics in patients with colorectal cancer (CRC) with molecular residual disease: Updated analysis from GALAXY study in the CIRCULATE-JAPAN. Gastrointestinal Cancers Symposium 2024;Abstract 6.
Module 14: Pancreatic Cancers
Abdelrahman Y et al. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. NPJ Precision Oncology 2024;8:27. Abstract
Arbour K et al. Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). ESMO 2023;Abstract 6520.
Bekaii-Saab T et al. Adagrasib in advanced solid tumors harboring a KRASG12C mutation. J Clin Oncol 2023;41(25):4097-106. Abstract
Boursi B et al. Analysis of BRCA1- and BRCA2-related pancreatic cancer and survival. JAMA Netw Open 2023;6(11):e2345013. Abstract
Hollebecque A et al. Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study. Gastrointestinal Cancers Symposium 2024;Abstract 94.
Murciano-Goroff Y et al. A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors. AACR 2023;Abstract CT028.
Murciano-Goroff Y et al. Dynamic changes in circulating tumor DNA (ctDNA) in patients treated with sotorasib for KRAS G12C mutant non-small cell lung cancer. AACR 2023;Abstract 1144.
Ohba A et al. Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial. ESMO 2023;Abstract 1616O.
O’Reilly EM et al. AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer. ASCO 2023;Abstract 2528.
Pant S et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: The phase 1 AMPLIFY-201 trial. Nature Med 2024;30(2):531-42. Abstract
Pant S et al. First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors. ASCO 2022;Abstract TPS2701.
Rojas L et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023;618(7963):144-50. Abstract
Sacher A et al. Single-agent divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N Engl J Med 2023;389(8):710-21. Abstract
Spira AI et al. Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS- selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-00. AACR-NCI-EORTC 2023;Abstract PR010.
Stickler J et al. Sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer. N Engl J Med 2023;388(1):33-43. Abstract
Wainberg Z et al. ARC-8: Phase 1/1b randomized study of quemliclustat + gemcitabine/nab-paclitaxel ± zimberelimab in patients with treatment-naive metastatic pancreatic adenocarcinoma. Gastrointestinal Cancers Symposium 2024;Abstract 665.
Wainberg ZA et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial. Lancet 2023;402(10409):1272-81. Abstract